The Structural Basis for the Immune Recognition of Factor VIII

因子 VIII 免疫识别的结构基础

基本信息

  • 批准号:
    10406902
  • 负责人:
  • 金额:
    $ 38.16万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-05-01 至 2024-04-30
  • 项目状态:
    已结题

项目摘要

Summary/Abstract (Project 1) The central hypothesis of this project is that intrinsic structural and dynamic features of fVIII are responsible for its immunogenicity. The basis for this hypothesis is the remarkable immunogenicity of fVIII compared to other proteins. Additionally, during the early immune response to fVIII, fVIII immune complexes may amplify the immune response through Fc receptor or B cell receptor (BCR), antigen presentation or other mechanisms. To address this hypothesis, a better understanding of the structures and dynamics of fVIII and fVIII immune complexes is required. There are three Specific Aims in this project. Aim 1 is to develop X-ray crystallographic structures of fVIII and fVIII immune complexes. Development of atomic level resolution X-ray structures of fVIII, activated fVIII and fVIII immune complexes is fundamental to a better understanding of the immune response to fVIII. The available fVIII X-ray structures are not at atomic level resolution. Structures of immune complexes of the fVIII C2 domain are available. However, there are no structures of immune complexes with full-length or B domain-deleted fVIII. We have developed a high-expression platform that yields sub-gram quantities of a fVIII construct designated HP47 for crystallographic trials. In preliminary studies, we have crystals of HP47 fVIII that diffract beyond 3.2 Å resolution and are refining the structure. Aim 2 is to characterize fVIII antibody epitopes and fVIII immune complexes by hydrogen deuterium exchange mass spectrometry (HDX MS), electron microscopy (EM) and surface plasmon resonance spectroscopy. These methods are state-of-the-art complementary methods to characterize epitopes. HDX MS mapping studies of the C1 and C2 domain have been performed by our group. We have now obtained HDX coverage of the ~ 250-kDa full-length fVIII molecule, which will be used to map immunodominant epitopes throughout the fVIII molecule. Aim 3 is to characterize fVIII immune complexes by sedimentation velocity analytical ultracentrifugation (SV AUC). IgG immune complexes can amplify the immune response to the cognate antigen. However, the role of fVIII immune complexes in the immune response to fVIII has not been explored. A combination of two or more IgG molecules that recognize non-overlapping epitopes hypothetically can form large immune complexes with molecular weights extending to megadaltons. SV AUC is the method of choice for identifying and characterizing large protein-protein complexes. In preliminary studies, we have determined the stoichiometry of binary fVIII/anti-A2 MAb 4A4 and fVIII/anti-C2 MAb 3D12 complexes and the ternary fVIII/4A4/3D12 complex. These studies will be extended to characterize the stoichiometries of immune complexes formed by additional important classes of anti-fVIII MAbs. X-ray crystallographic, HDX MS, EM and SV AUC results be combined to develop models of fVIII IgG immune complexes. Additionally, the immune complexes characterized in Aim 3 will be tested in cellular and in vivo systems in collaboration with Project 2 for their possible contribution to the immunogenicity of fVIII.
摘要/摘要(项目1) 这个项目的中心假设是FVIII的内在结构和动态特征负责 它的免疫原性。这一假说的基础是FVIII与其他疫苗相比具有显著的免疫原性 蛋白质。此外,在对FVIII的早期免疫反应中,FVIII免疫复合体可能会放大 免疫反应通过Fc受体或B细胞受体(BCR)、抗原提呈或其他机制实现。至 解决这一假说,更好地理解FVIII和FVIII免疫的结构和动力学 复合体是必需的。这个项目有三个具体目标。目标1是发展X射线结晶学 FVIII和FVIII免疫复合物的结构。FVIII原子能级分辨X射线结构的发展, 激活的FVIII和FVIII免疫复合体是更好地理解免疫反应的基础 Fviii.可用的FVIII X射线结构不是原子级别的分辨率。沙门氏菌免疫复合物的结构 FVIII C2域可用。然而,没有全长或B的免疫复合物的结构 域已删除Fviii。我们已经开发了一种高表达平台,可以产生亚克量的FVIII 构建用于结晶学实验的HP47。在初步研究中,我们发现了HP47FVIII的晶体 衍射率超过3.2?分辨率,并且正在改进结构。目的2是鉴定FVIII抗体表位 和FVIII免疫络合物的氢氚交换质谱学(HDX MS),电子 显微镜(EM)和表面等离子体共振谱。这些方法是最先进的。 表位特征的互补方法。C_1和C_2结构域的HDX MS作图研究 都是由我们团队表演的。我们现在已经获得了~250 kDa全长FVIII分子的HDX覆盖, 它将被用于绘制整个FVIII分子的免疫优势表位图。目标3是描述FVIII的特征 沉降速度分析超速离心法免疫复合物(SV AUC)。免疫球蛋白免疫复合物 可以放大对同源抗原的免疫反应。然而,FVIII免疫复合体在人类免疫系统中的作用 对FVIII的免疫应答还没有被探索。识别两个或多个免疫球蛋白G分子的组合 假设不重叠的表位可以形成大的免疫复合体,其分子量可以延伸到 百万吨级。SV AUC是识别和表征大型蛋白质-蛋白质复合体的首选方法。 在初步研究中,我们测定了FVIII/抗A2单抗4A4和FVIII/抗C2的化学计量比 单抗3D12和FVIII/4A4/3D12三元配合物。这些研究将扩展到表征 由其他重要的抗FVIII单抗形成的免疫复合体的化学计量比。X射线 结晶学、HDX-MS、EM和SV AUC结果相结合建立FVIII免疫球蛋白模型 复合体。此外,将在细胞和体内测试AIM 3中表征的免疫复合体 与项目2合作,为FVIII的免疫原性做出可能的贡献。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

John S. Lollar其他文献

Cryo-EM Structure of Coagulation Factor VIII Bound to a Patient-Derived Anti-A2 Domain Antibody Inhibitor
  • DOI:
    10.1182/blood-2023-182304
  • 发表时间:
    2023-11-02
  • 期刊:
  • 影响因子:
  • 作者:
    Kenneth C Childers;Jordan Vaughan;John S. Lollar;Christopher B Doering;Carmen Helena Coxon;P. Clint Spiegel
  • 通讯作者:
    P. Clint Spiegel

John S. Lollar的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('John S. Lollar', 18)}}的其他基金

Unraveling the immune response to factor VIII
揭示对因子 VIII 的免疫反应
  • 批准号:
    10406900
  • 财政年份:
    2018
  • 资助金额:
    $ 38.16万
  • 项目类别:
Unraveling the immune response to factor VIII
揭示对因子 VIII 的免疫反应
  • 批准号:
    9522256
  • 财政年份:
    2018
  • 资助金额:
    $ 38.16万
  • 项目类别:
Novel Assays Predicting Phenotypic Heterogeneity in Severe Hemophilia
预测严重血友病表型异质性的新方法
  • 批准号:
    8464235
  • 财政年份:
    2013
  • 资助金额:
    $ 38.16万
  • 项目类别:
Molecular Heterogeneity in FVIII Inhibitor Patients
FVIII 抑制剂患者的分子异质性
  • 批准号:
    8464234
  • 财政年份:
    2013
  • 资助金额:
    $ 38.16万
  • 项目类别:
Biorepository Core
生物样本库核心
  • 批准号:
    8464242
  • 财政年份:
    2013
  • 资助金额:
    $ 38.16万
  • 项目类别:
The Immune Response to Factor Vlll
对因子 VIII 的免疫反应
  • 批准号:
    8391965
  • 财政年份:
    2012
  • 资助金额:
    $ 38.16万
  • 项目类别:
Eradication of FVIII Inhibitors using Gene-Based Therapy
使用基因疗法根除 FVIII 抑制剂
  • 批准号:
    8391966
  • 财政年份:
    2012
  • 资助金额:
    $ 38.16万
  • 项目类别:
Biological Variation in Hemophilia
血友病的生物学变异
  • 批准号:
    8464228
  • 财政年份:
    2012
  • 资助金额:
    $ 38.16万
  • 项目类别:
Biological Variation in Hemophilia
血友病的生物学变异
  • 批准号:
    8656781
  • 财政年份:
    2012
  • 资助金额:
    $ 38.16万
  • 项目类别:
Biorepository Core
生物样本库核心
  • 批准号:
    8392594
  • 财政年份:
    2012
  • 资助金额:
    $ 38.16万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 38.16万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 38.16万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 38.16万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.16万
  • 项目类别:
    Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 38.16万
  • 项目类别:
    Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 38.16万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 38.16万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
  • 批准号:
    10639161
  • 财政年份:
    2023
  • 资助金额:
    $ 38.16万
  • 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
  • 批准号:
    10752441
  • 财政年份:
    2023
  • 资助金额:
    $ 38.16万
  • 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
  • 批准号:
    10867639
  • 财政年份:
    2023
  • 资助金额:
    $ 38.16万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了